Biree Andemariam is an Oncology physician affiliated with UConn Health. OpenAlex indexes 168 publications with 2,049 citations (h-index 22); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
263 Farmington Ave
Farmington, CT 060300001
Telephone
860-679-2100Registry record last updated 26 Sept 2022.
Clinical trials
- Hypoxic Red Blood Cells in Sickle Cell Anemia
Sponsor: Hemanext
- Sickle Cell Hemoglobinopathies and Bone Health
Sponsor: UConn Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Agios Pharmaceuticals, Inc.Program year202527 payments$56,147openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year202511 payments$31,036openpaymentsdata.cms.gov ↗
- Novo Nordisk Health Care AGProgram year20256 payments$22,131openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
100%Hemoglobin S Polymerization Inhibitor100%Oxbryta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission
The Lancet Haematology
2023 - Economic and clinical burden of managing transfusion-dependent β-thalassemia in the United States
Journal of Medical Economics
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Martha Radford, MD
UConn Health
David Steffens, MD
UConn Health
Peter Albertsen, MD
UConn Health
Mark Metersky, MD
UConn Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”